Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Shares Outstanding (Diluted Average): 2010-2025

Historic Shares Outstanding (Diluted Average) for Anika Therapeutics (ANIK) over the last 8 years, with Sep 2025 value amounting to $14.4 million.

  • Anika Therapeutics' Shares Outstanding (Diluted Average) fell 2.37% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 2.37%. This contributed to the annual value of $15.4 million for FY2015, which is 0.49% up from last year.
  • Per Anika Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $14.4 million for Q3 2025, which was up 0.85% from $14.3 million recorded in Q1 2025.
  • Anika Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $14.8 million for Q2 2024, and its period low was $14.3 million during Q1 2025.
  • Over the past 3 years, Anika Therapeutics' median Shares Outstanding (Diluted Average) value was $14.7 million (recorded in 2023), while the average stood at $14.6 million.
  • In the last 5 years, Anika Therapeutics' Shares Outstanding (Diluted Average) rose by 1.29% in 2023 and then dropped by 2.73% in 2025.
  • Anika Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $14.6 million in 2022, then grew by 0.38% to $14.7 million in 2023, then climbed by 0.75% to $14.8 million in 2024, then declined by 2.37% to $14.4 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $14.4 million in Q3 2025, compared to $14.3 million in Q1 2025 and $14.8 million in Q3 2024.